Som sikkerhedsforanstaltning anbefalede CPMP, at produktresuméet for lægemidler indeholdende loratadin skulle ændres, så det indeholdt en angivelse af, at det ikke anbefales at anvende loratadin under graviditet.
As a precautionary measure the CPMP recommended, that the SPC for loratadine containing medicinal products should be amended to state that the use of loratadine during pregnancy is not recommended;